InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.735 -0.195 (-20.97%)+
Announcement
Release
18 Feb 2026 12:56PM
Price at Release
$0.930
Full Release
download
Summary
Orthocell Limited, a regenerative medicine company, announced the receipt of a $3.0 million R&D Tax Incentive refund from the Australian Federal Government for the financial year ending 30 June 2025. This non-dilutive funding enhances Orthocell's cash reserves to $49.6 million, bolstering their efforts to commercialize their flagship nerve repair product, Remplir™, across the Americas and Asia Pacific. The R&D Tax Incentive provides substantial economic support to Australian companies undertaking innovative R&D activities, offering rebates up to 48.5% of expenditures. Orthocell remains focused on leveraging this support to drive the market adoption of Remplir™, backed by a robust, debt-free financial position.
Key Points
  • Orthocell Limited received a $3.0 million R&D Tax Incentive refund.
  • The company's cash reserves increased to $49.6 million post-refund.
  • The refund supports the commercialisation of their Remplir™ product.
  • Orthocell plans to drive rapid market adoption of Remplir™.
  • The R&D Tax Incentive is an Australian Government program providing rebates of up to 48.5%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.